AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUN 27 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - The ongoing emergence of antibacterial-resistant strains of Pneumococcus, despite approval of the 23-valent pneumococcal polysaccharide (PPS) vaccine, has renewed interest in answering a common question: Why doesn't the vaccine work better in the elderly?
"The protective efficacy of this vaccine for the growing population of adults aged >65 years remains controversial," wrote J.B. Rubins, University of Minnesota School of Medicine, and associates in Drugs and Aging. "The apparent effectiveness of pneumococcal immunization in clinical studies of elderly adults has varied depending upon whether a reduction in pneumococcal colonization, pneumonia, bacteremia, or death was used as an outcome."
These studies have found a protective efficacy from the vaccine anywhere from 56% to 81%, reported Rubins and colleagues. Its ability to augment the benefit of the influenza vaccine in preventing community-acquired pneumonia may make it especially useful for the elderly, they added.
Among the possible reasons the vaccine does not meet expectations in that population are infection with nonvaccine serotypes, inadequate antibody responses, or compromised, nonhumoral host defenses.
Future research should test evolving versions of the vaccine, including newer protein conjugates or DNA vaccines, in elderly candidates who are ...
Source: HighBeam Research, Reason Behind Vaccine's Lack Of Efficacy In Elderly Remains...